Cleerly is a digital healthcare company that utilizes AI-based analysis of coronary computed tomography angiography (CCTA) imaging to quantify and characterize atherosclerosis, enabling precise identification of heart disease. This approach addresses the issue that over 70% of heart attack victims are misclassified as low risk by traditional methods, allowing for earlier and more personalized treatment plans.
Funding
$410.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods of assessing heart disease risk often misclassify individuals, with a significant percentage of heart attack victims being deemed low risk. These conventional approaches rely on indirect markers and may miss critical indicators of atherosclerosis, such as mild arterial narrowing. This can lead to delayed or inadequate treatment, increasing the likelihood of adverse cardiac events.
Solution
Cleerly offers an AI-powered digital healthcare platform that analyzes coronary computed tomography angiography (CCTA) images to precisely quantify and characterize atherosclerosis. By directly measuring plaque buildup in the heart's arteries, Cleerly provides clinicians with a more accurate assessment of a patient's risk of heart attack. The platform's AI algorithms identify and define the types of plaque present, enabling personalized treatment plans tailored to each patient's specific condition. This approach facilitates earlier intervention and more effective management of heart disease throughout the care continuum, improving both clinical and financial outcomes.
Target Audience
The primary users are physicians, including cardiologists and radiologists, and healthcare systems seeking advanced tools for early and accurate detection and management of heart disease.
Features
- AI-based analysis of CCTA images for precise quantification and characterization of atherosclerosis
- Measurement of plaque buildup in the heart's arteries, rather than indirect risk markers
- Identification and definition of different types of plaque
- Personalized treatment plans based on individual patient's condition
- Digital and print tools that transform complex imaging data into actionable clinical insights
- Reporting tailored to each stakeholder, improving overall clinical and financial outcomes